SCHEMBL25317459

SCHEMBL25317459

CC1NC(=O)c2ccc(N)cc21

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MKNK2 Q9HBH9 3/20 0.47
MKNK1 Q9BUB5 3/20 0.47
CA12 O43570 2/20 0.41
CA9 Q16790 2/20 0.41
NPC1 O15118 3/20 0.38
ALDH1A1 P00352 3/20 0.38
RAB9A P51151 3/20 0.38
TSHR P16473 3/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
TP53 P04637 1/20 0.38
CYP3A4 P08684 1/20 0.38
MAPK1 P28482 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
PTPRC P08575 2/20 0.37
LMNA P02545 2/20 0.37
MEN1 O00255 1/20 0.37
APAF1 O14727 1/20 0.37
TDP2 O95551 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12219994 0.87 MKNK2 (0.40) MKNK2MKNK1CA12CA9NPC1
SCHEMBL30512998 0.81 CA12 (0.39) MKNK2MKNK1CA12CA9NPC1
SCHEMBL29978011 0.81 ALDH1A1 (0.47) MKNK2MKNK1NPC1ALDH1A1CA1
SCHEMBL28387305 0.81 ALDH1A1 (0.47) MKNK2MKNK1NPC1ALDH1A1CA1
SCHEMBL20529362 0.79 MKNK2 (0.46) MKNK2MKNK1CA9TP53CA1
SCHEMBL14991575 0.79 MKNK2 (0.46) MKNK2MKNK1CA1CA2MEN1
SCHEMBL18786964 0.79 MKNK2 (0.46) MKNK2MKNK1CA9CA1CA2
SCHEMBL30991826 0.77 CA12 (0.41) CA12CA9NPC1ALDH1A1RAB9A
SCHEMBL22080750 0.77 CA12 (0.41) CA12CA9NPC1ALDH1A1RAB9A
SCHEMBL20529019 0.77 MKNK2 (0.44) MKNK2MKNK1ALDH1A1RAB9ATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250122173-A1 MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE REDX PHARMA LTD (GB) 2025-04-17 US disclosed
EP-4466071-A1 MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE (ROCK) Redx Pharma Limited (GB) 2024-11-27 EP disclosed
CN-118632845-A Modulators of Rho-associated protein kinase (ROCK) 莱德克斯制药有限公司 2024-09-10 CN disclosed
WO-2023139379-A1 MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE (ROCK) REDX PHARMA PLC (GB) 2023-07-27 WO disclosed
WO-2023139379-A1 MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE (ROCK) REDX PHARMA PLC (GB) 2023-07-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250122173-A1 MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE ROCK1, ROCK2, RHOA MKNK2 142/4885MKNK1 175/4885CA12 4481/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.